Siblings Books/Book Section [5/6] Periodical Articles [82/82] Collection Statistics Item counts issued in 3 years:2(11.76%) Items With Fulltext:14(82.35%) Download counts of the item Download times greater than 0:14(100.00%) Download times greater than 100:13(92.86%) Total Bitstream Download Counts:6903(15.13%) Last Update: 2024-11-28 17:38 Top Upload Loading... Top Download Loading... Recent Submissions Atezolizumab plus bevacizumab for p... A prospective phase II study of biw... TCOG T1308 study: The final results... Assessing benefit and consistency o... Prediction of hepatitis B virus rea... Prevention of chemotherapy-induced ... Long-term outcome of chemotherapy-i... KRAS mutation status-stratified ran... Impact of ROS1, ALK, and/or MET exp... EGFR variant III act as the major d...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 1-17 of 17. (1 Page(s) Totally) 1  View [10|25|50] records per page

Date	Title	Relation
2023-06	Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: Focusing on hepatic safety and viral kinetics	Journal of Hepatology. 2023 Jun;78:S588-S589.
2022-02-01	A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma	Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):550.
2018-11	TCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer	Annals of Oncology. 2018 Nov;29(Suppl. 9):50.
2017	Prediction of hepatitis B virus reactivation in lymphoma patients with resolved hepatitis B virus infection who received rituximab-containing chemotherapy: The roles of antiHBc/antiHBs quantification	Journal of Hepatology. 2017;66(1, Suppl.):S259.
2016-11-11	Assessing benefit and consistency of treatment effect under a discrete random effects model in multiregional clinical trials	Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. 2016 Nov 11:127-136.
2015-04	Long-term outcome of chemotherapy-induced HBV reactivation in lymphoma patients with resolved HBV infection	Journal of Hepatology. 2015 Apr;62, Suppl. 2:S563.
2014-04	Prevention of chemotherapy-induced hbv-related hepatitis flare in lymphoma patients with resolved hbv infection: Cost analysis	Journal of Hepatology. 2014 Apr;60(1):S206-S207.
2014-01	Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial	Journal of Clinical Oncology. 2014 Jan;32(3 Suppl):Abstract number 267.
2013-05	KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial	Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number 4018.
2013-04	Comparing multiple testing correction methods between two softwares for single nucleotide polymorphisms association analyses: Using OPRD1 and diastolic blood pressure in methadone maintenance patients as an example	2013 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB). 2013 Apr:154-159.
2013-04	EGFR variant III act as the major determinant factors in the EGFR/PI3K/AKT pathway for the survival outcome of oral cancer patients	Cancer Research. 2013 Apr;73(8 Suppl. 1):Abstract number 2390.
2012-03	CYP1A2 genetic polymorphisms associated with antidepressant escitalopram metabolism and adverse reactions at early stage	Clinical Pharmacology and Therapeutics. 2012 Mar;91(Suppl. 1):S62.
2011-09-23	A phase II study of neoadjuvant bio-chemotherapy with Cetuximab, Paclitaxel, and Cisplatin (CPC) followed by Cetuximab-based concurrent bio-radiotherapy in high-risk locally advanced head and neck cancer - representative of head and neck cancer study grou	European Journal of Cancer. 2011 Sep 23;47:S547-S548.
2011-05	Genetic polymorphisms in PXR associated with serum concentration and metabolism to treatment with the antidepressant paroxetine	Drug Metabolism Reviews. 2011 May;43(Suppl.1):71.
2011-05	The genetic polymorphisms in ALDH2 influence the methadone dose and adverse reactions in patients with heroin addiction	Drug Metabolism Reviews. 2011 May;43(Suppl.1):26.
2011-05	Genetic polymorphisms of CYP2C19 associated with the side effect and serum concentrations of antidepressant paroxetine	Drug Metabolism Reviews. 2011 May;43(Suppl.1):25-26.
2011-05	Opioid receptor Mu1 genetic polymorphisms influence QT prolongation and insomnia in methadone maintenance patients	Biological Psychiatry. 2011 May;69(9 Suppl.1):229S-230S.

Showing items 1-17 of 17. (1 Page(s) Totally) 1  View [10|25|50] records per page